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Abstract
Ebola Zaire virus is highly pathogenic for humans, with case fatality rates approaching 90% in large outbreaks in Africa. The
virus replicates in macrophages and dendritic cells (DCs), suppressing production of type I interferons (IFNs) while inducing
the release of large quantities of proinflammatory cytokines. Although the viral VP35 protein has been shown to inhibit IFN
responses, the mechanism by which it blocks IFN production has not been fully elucidated. We expressed VP35 from a
mouse-adapted variant of Ebola Zaire virus in murine DCs by retroviral gene transfer, and tested for IFN transcription upon
Newcastle Disease virus (NDV) infection and toll-like receptor signaling. We found that VP35 inhibited IFN transcription in
DCs following these stimuli by disabling the activity of IRF7, a transcription factor required for IFN transcription. By yeast
two-hybrid screens and coimmunoprecipitation assays, we found that VP35 interacted with IRF7, Ubc9 and PIAS1. The latter
two are the host SUMO E2 enzyme and E3 ligase, respectively. VP35, while not itself a SUMO ligase, increased PIAS1-
mediated SUMOylation of IRF7, and repressed Ifn transcription. In contrast, VP35 did not interfere with the activation of NF-
kB, which is required for induction of many proinflammatory cytokines. Our findings indicate that Ebola Zaire virus exploits
the cellular SUMOylation machinery for its advantage and help to explain how the virus overcomes host innate defenses,
causing rapidly overwhelming infection to produce a syndrome resembling fulminant septic shock.
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Introduction
Ebola Zaire virus (EBOV) causes severe hemorrhagic fever in
humans, with case fatality rates as high as 90% in large outbreaks in
Africa [1]. Dendritic cells (DCs) and macrophages are the main initial
targets of EBOV infection [2–4]. A series of studies have shown that
EBOV inhibits the production of type I IFN by these cells, while
stimulating them to release large quantities of proinflammatory
cytokines [5–7]. As a result, the virus spreads rapidly to cause an
intense systemic inflammatory syndrome resembling septic shock [8].
The impaired innate immunity might also inhibit subsequent
adaptive responses [5–7,9]. A series of reports indicate that EBOV
selectively weakens production of type I interferons (IFNs), while
allowing production of other proinflammatory cytokines [5–7].
Epidemiological and animal studies support the idea that type I
IFNs play a protective role against EBOV infection. Immunocom-
petent mice, which are resistant to infection with wild-type EBOV,
become lethally infected when treated with antibody to type I IFN
[10]. Moreover, IFNa production correlates with increased resistance
in infected mice [11]. Further, administration of type I IFNs confers
partial protection against EBOV infected monkeys [12]. Although
type I IFNs were shown to be produced upon lethal EBOV infection
in an animal model study, a study during an outbreak of Ebola
hemorrhagic fever showed that IFNa levels were significantly higher
in surviving patients than those with fatal infection [5,6].
Two EBOV proteins, VP24 and VP35, are responsible for the
suppression of type I IFN production [7,13–15]. VP24 inhibits the
cellular response to exogenous IFN by interacting with karyo-
pherin a1, preventing the nuclear accumulation of tyrosine-
phosphorylated Stat1 and Stat2 [15,16]. VP35, on the other hand,
has been shown to inhibit the activation of the transcription factor
IRF3 by binding to dsRNA and inhibiting retinoic acid induced
gene-I (RIG-I) signaling [13,14,17]. VP35 is also reported to
interfere with the activation of the dsRNA-binding kinase, PKR
[18]. However, an EBOV variant that was attenuated as a result of
a point mutation in the VP35 RNA-binding domain was still
capable of inhibiting IFNb induction, suggesting the existence of
another inhibitory mechanism [17,19,20]. Pertinent to this issue,
Prins, et al., recently reported that VP35 impairs the activity of
kinases important for IRF3 activation [21].
Although studies of VP35-mediated IFN antagonism have so far
focused on the inhibition of IRF3, it has been demonstrated that a
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induction of type I IFN after virus infection, as evidenced by the
abrogation of IFN production in Irf7 2/2 mice, but not in Irf3
2/2 mice [22–24]. IRF7, although similar to IRF3 in structure,
differs in its expression and its mode of action [22,25,26]. The
dominant role that IRF7 plays in IFN production in DCs has also
been established: plasmacytoid DCs (pDCs), which produce the
largest amounts of type I IFNs, express IRF7 at high levels, and its
expression is further enhanced by IFN produced by positive
feedback [23,27–29]. In light of this and the evidence that DCs are
a primary site of early EBOV infection, it seems important to
investigate the mechanism of VP35’s IFN antagonism in DCs,
focusing on its effects on IRF7.
DCs are key players of innate immunity [30,31]. Distributed
widely in the body, DCs are among the first cells to recognize
pathogen signals through toll-like receptors (TLRs) and other
receptors [32]. In response, they produce large amounts of type I
IFNs [27,33], which in turn stimulate DC maturation to establish
host resistance and facilitate the initiation of adaptive immune
responses. The importance of studying EBOV infection of DCs
gains additional urgency given the reports that some aspects of
TLR signaling and pathogen processing in DCs are distinct from
those in other cells [34]. For example, the RIG-I system is shown
to be dispensable for IFN production in pDCs [35]. Moreover,
type I IFN production in DCs involves another transcription
factor, IRF8, that acts uniquely in the second phase of IFN
transcription in DCs [36].
Here we report that VP35 potently inhibits type I IFN induction
in mouse pDCs and other conventional (c)DCs in response to virus
infection or TLR signaling, without inhibiting NF-kB activation. A
yeast two-hybrid screen and co-immunoprecipitation analysis
showed that VP35 interacts with IRF7 and IRF3 as well as two
other cellular proteins, PIAS1 and Ubc9. The latter proteins are
involved in the small ubiquitin-like modifier (SUMO) conjugation
cascade [37–39]. SUMO proteins (SUMO1 through SUMO4) are
composed of ,100 amino acids, conserved from yeast to humans.
They are covalently conjugated to a variety of proteins through
lysine residues in a reversible manner, modulating their activities.
SUMO modification affects many cellular processes, including
stress response, transcription and protein-protein interactions.
Similar to ubiquitination, the SUMO modification requires three
step enzymatic reactions involving the E1 enzymes, Ubc9, an E2
enzyme and E3 ligases such as PIAS family proteins.
We show that VP35 augments SUMOylation of IRF7, leading
to increased inhibition of IFN transcription by IRF7 that is at least
in part mediated by PIAS1. A similar effect of VP35 was noted for
IRF3. Supporting the view that SUMOylation is involved in the
IFN transcription, we recently reported that IRF3 and IRF7 are
modified by SUMO1 through SUMO3 in fibroblasts after viral
infection. In that report SUMO molecules were covalently
conjugated to IRF3/7 through TLR and RIG-I signaling which
was linked to reduced IFN transcription, indicating that SUMO
modification of IRF3/7 is a part of the negative feedback loop of
normal IFN signaling [40]. Our results illustrates that VP35 makes
use of this cellular mechanism to weaken host innate immunity.
Results
VP35 from wild-type and mouse-adapted EBOV inhibits
type I IFN production in DCs
VP35 derived from a mouse-adapted EBOV variant was tagged
with the enhanced green fluorescent protein (EGFP) or hemag-
glutinin (HA), cloned in the pMSCV retroviral vector, and
introduced into bone marrow (BM)-derived DCs cultured in the
presence of fms-like tyrosine kinase 3 ligand (Flt3L) [36,41]. In the
presence of Flt3L, all four major DC subsets are generated
[30,41]. Flow cytometry data in Figure 1A (upper panel) showed
that EGFP-tagged VP35 (VP35-EGFP) was expressed in essen-
tially all BMDCs in the culture, showing similar fluorescent
intensity as cells expressing free EGFP. As shown in Figure 1A
(middle and bottom panel), introduction of VP35 vector did not
inhibit the generation of DCs, as verified by the expression of
CD11c, the pan-DC marker on the cells transduced with VP35-
EGFP, EGFP alone or mock transduced. Furthermore, the
percentage of pDCs, as assessed by the B220 marker, was similar
among these cells (between 35% and 50%), indicating that VP35
did not affect the ratio of pDCs and cDCs. Immunostaining
analysis in Figure 1B showed that HA-tagged VP35 (VP35-HA)
was present largely in the cytoplasm, consistent with the
predominantly cytoplasmic localization of VP35 reported earlier
[14]. Thus, VP35 can be efficiently expressed in BMDCs without
inhibiting their development. The mouse-adapted VP35 differs
from that of the wild-type Zaire EBOV in one amino acid (position
12, substituting V for A). We also constructed a vector for EGFP-
tagged VP35 from the wild-type EBOV and found that this VP35
was expressed in a manner similar to the mouse adapted VP35
and its expression also did not interfere with the DC development
(see below). Both vectors expressed the VP35 proteins of expected
molecular mass, as judged by immunoblot analysis (Figure S1A).
Induction of type I IFNs was then tested in these DCs following
infection with the Newcastle Disease virus (NDV). We have
previously shown that both pDCs and cDCs produce high levels of
type I IFNs after NDV infection [36]. In Figure 2A, we examined
IFNa protein production in DCs expressing VP35-EGFP. NDV
infection led to high IFNa production in control DCs expressing
free EGFP, whereas little IFNa was produced in DCs expressing
VP35-EGFP. Paralleling these results, NDV infection stimulated
robust IFNa transcript expression in control DCs, but the
expression was very meager in VP35-EGFP expressing DCs
(Figure 2B). Similarly, NDV infection stimulated IFNb transcript
induction in control DCs, but it failed to do so in DCs expressing
VP35-EGFP (Figure 2C). Since DCs produce type I IFNs in
Author Summary
Ebola Zaire virus causes severe hemorrhagic fever in
humans that is fatal in almost 90% of cases. The rapid
spread of the virus to macrophages and dendritic cells
results in the release of high levels of inflammatory
cytokines, causing shock and bleeding. The ability of Ebola
virus to overwhelm host defenses is believed to result from
its suppression of the type I interferon (IFN) response. The
Ebola viral protein VP35 is known to block IFN responses,
but the precise mechanisms have not been identified. We
expressed VP35 in mouse dendritic cells and found that
the cells failed to develop a normal IFN response when
infected with Newcastle Disease virus. By a yeast two-
hybrid system and other biochemical experiments, we
showed that the blockade resulted from the conjugation
of a Small Ubiquitin-like Modifier (SUMO) protein to IRF-7,
the principal cellular factor required for IFN gene
expression. However, the cells were still able to activate
NF-kB, a transcription factor responsible for the release of
proinflammatory cytokines. Our findings provide a first
example where a virus hijacks the host SUMO system to
undermine innate immunity, and help to explain how
Ebola virus spreads rapidly in lymphoid tissues to cause a
lethal inflammatory syndrome.
Ebola VP35 Inhibits Innate Immunity by SUMOylation
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TLR9, we tested the effect of VP35-EGFP on CpG DNA-induced
IFN transcription [32,33]. In Figure 2D, VP35 strongly inhibited
IFNa induction by CpG, supporting the idea that VP35 can
inhibit type I IFN induction independently of dsRNA binding
activity.
Both the mouse-adapted and wild-type VP35 proteins inhibited
IFN induction in DCs after NDV and CpG stimulation
(Figure 2A–D, Figure S1B, S1C). Thus, all studies presented in
the remainder of this paper were conducted with the mouse-
adapted VP35. It is of note that VP35-EGFP, VP35-HA and
VP35 without a tag equally inhibited IFN induction (see below).
The complete induction of IFN in DCs involves two steps: initial
transcription is triggered by IRF7, while the second round of
transcription is induced by the IFN feedback response [27,36]. If
VP35 inhibits IFN transcription in the feedback phase, it would
therefore inhibit the expression of other IFN stimulated genes as
well. As shown in Figure 2E, VP35-EGFP did not inhibit
expression of Ifit1, a typical IFN stimulated gene, and only
modestly inhibited IRF7 induction. In contrast, other investigators
Figure 1. Expression of VP35 in pDCs and cDCs. A: BMDCs were transduced with pMSCV vector for VP35-EGFP or free EGFP (Ctrl-EGFP) on day
2 and allowed to develop in Flt3L for a total of 8 days. EGFP signals and expression of CD11c and B220 were monitored by flow cytometry. The
bracketed areas indicate pDC population and the numbers represent the percentages in the total DC population. B: DCs were transduced with
pMSCV vector for VP35-HA. On day 8 the cells were fixed, immunostained with antibody for HA followed by counterstaining with Hoechst for DNA.
On the left is an image by differential interference contrast (DIC).
doi:10.1371/journal.ppat.1000493.g001
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stimulated transcription, strongly inhibited expression of these
genes [15,16]. These data indicate that VP35 inhibits the initial
phase of IFN transcription in DCs.
VP35 does not inhibit NF-kB activation
Pathogen signaling activates two separate transcription path-
ways involving IRF3/7 and NF-kB [32]. The former stimulates
transcription of IFNas, while the latter triggers that of proin-
flammatory cytokines, although both IRF3/7 and NF-kB are
involved in IFNb transcription [22,32,42]. We sought to assess the
role of VP35 in the activation of NF-kB, considering that EBOV
impairs type I IFN production, while often enhancing the
production of other proinflammatory cytokines triggered by NF-
kB [6,7]. As seen in Figure 3A, NDV infection stimulated the
expression of typical NF-kB targets, TNFa and IkBa, equally well
in control and VP35-EGFP expressing DCs [42]. These data
suggest that VP35 inhibits IRF3/7 dependent transcription
without affecting NF-kB mediated transcription in DCs. To
further assess the effect of VP35 on NF-kB activation, we looked
for the nuclear translocation of p65/RelA, the major activating
component of NF-kB [43]. Immunostaining data in Figure 3B
showed that before NDV stimulation, p65/RelA was predomi-
nantly in the cytoplasm, but upon stimulation the majority of p65/
relA translocated into the nucleus, both in control and VP35-HA
expressing DCs. Of ,200 stimulated DCs inspected, more than
85% displayed p65/RelA in the nucleus, irrespective of VP35-HA
expression. These data support the idea that VP35 does not inhibit
NF-kB activation in DCs.
VP35 inhibits the recruitment of IRF7 to type I IFN genes
in DCs
To ascertain whether VP35 inhibits IFN production by
disabling IRF7, immunoprecipitation (ChIP) assay was carried
out to examine the binding of IRF7 to the Ifn genes in DCs.
Chromatin from control and VP35-HA-expressing DCs was
precipitated with anti-IRF7 antibody, and precipitated DNA was
tested for the Ifna4 and Ifnb genes by quantitative (q) PCR [36]. In
control DCs, IRF7 bound to both the Ifna4 and Ifnb genes after
NDV infection, but not after mock infection (Figure 4A). In
contrast, little IRF7 binding was detected in VP35-HA-expressing
DCs with or without NDV infection. In both cases, control IgG
gave signals at background levels. These results indicate that VP35
blocks virus-induced recruitment of IRF7 to Ifn genes. Further
supporting inhibition of IRF7 recruitment, VP35 from the wild-
type EBOV similarly blocked NDV triggered IRF7 recruitment in
these DCs (Figure S1D).
VP35 inhibits IRF7-dependent IFNb promoter activity
To further investigate VP35 inhibition of IRF7 function, IFNb
reporter assays were performed in 293T cells expressing IRF7 and
VP35-HA (Figure 4B). As expected, transfection of IRF7 alone
without VP35-HA enhanced IFNb promoter activity even before
infection, and NDV infection increased reporter activity by about
two-fold. In both cases, cotransfection of VP35-HA inhibited
IFNb promoter activity by about 40%, suggesting that VP35
directly targets IRF7. In Figure 4C, VP35 truncations lacking the
N-terminal or C-terminal half of VP35 (VP35-N and VP35-C)
were tested for IFNb promoter activity (see a VP35 truncation
map in Figure 5B). Both truncations inhibited IFNb promoter
activity in a dose-dependent manner (see the bottom panel of
Figure 4C for the levels of VP35 protein expression). The
inhibition by VP-35C might have been expected, because dsRNA
binding activity of VP35 resides in the C-terminal region [17].
These data indicate that the N- and C-terminal halves of VP35
both contribute to the inhibition of IRF7-mediated IFNb
promoter activity.
Figure 2. VP35 inhibits induction of IFNa and IFNb in DCs. A
and B: DCs transduced with VP35-EGFP (VP35, open bar) or free GFP
(ctrl, solid bar) were infected with NDV for indicated times. IFNa protein
production (A) and Ifna transcript expression (B) were monitored by
ELISA and qRT-PCR, respectively. Values in these experiments (and all
below) represent the average of three determinations +/2S.D. C: DCs
transduced as above were infected with NDV for 5 h or mock infected
and tested for Ifnb transcripts as in B. D: DCs transduced as above were
stimulated with CpG DNA (1 mg/ml) for indicated times and Ifna
transcripts were measured as in B. E: DCs transduced as above or with
VP24-EGFP were stimulated with IFNb (100 U/ml) (solid bar) or vehicle
(open bar) for 8 h and expression of Ifit1 and Irf7 transcripts was
monitored by qRT-PCR.
doi:10.1371/journal.ppat.1000493.g002
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yeast two-hybrid screen
The above data indicated that VP35 acts on a step downstream
from pathogen signaling to disable the activity of IRF7 without
affecting the activation of NF-kB. To gain a mechanistic clue for
VP35 action, we searched for proteins that bind to VP35 by a
yeast two-hybrid screen. cDNA libraries were constructed from
NDV-stimulated DCs and screened with a full-length VP35 as a
bait. As shown in Figure 5A, screening of two libraries yielded a
number of clones implicated in the SUMO conjugation pathway,
including Ubc9, the protein inhibitor of activated STAT (PIAS1),
and Topors. Ubc9 is the sole E2 enzyme for SUMOylation, and
PIAS1 is a SUMO E3 ligase important for IFN signaling
[37,38,44,45]. Topors also acts as a SUMO E3 ligase for some
substrates [46]. These results pointed to a link between VP35 and
the host cell SUMO conjugation machinery.
VP35 interacts with both PIAS1 and IRF7
To further study a potential connection between VP35 and the
SUMOylation machinery, co-immunoprecpitation (Co-IP) analy-
sis was performed using 293T cells expressing Flag-tagged PIAS1
(Flag-PIAS1) and VP35-HA. In Figure 5B, Flag-PIAS1 copreci-
pitated full-length VP35, but neither of the truncated forms of
VP35. Immunoblot analysis of whole cell extracts (WCE) showed
that PIAS1 and VP35 were properly expressed in transfected cells.
These data indicate that VP35 interacts with PIAS1, for which
both the N- and C-terminal regions are required. We next asked if
VP35 could bind to IRF7. As seen in Figure 5C, Flag-IRF7 indeed
coprecipitated full-length VP35, demonstrating a direct VP35-
IRF7 interaction. Further, Flag-IRF7 precipitated VP35-N, but
not VP35-C, indicating that VP35-IRF7 interaction is mediated
by the N-terminal half of VP35. Similar Co-IP experiments found
that VP35 interacted with IRF7 before and after NDV infection,
showing that VP35 interacts with both the constitutive and
activated forms of IRF7 (Figure S2A).
The above results suggested the possibility that VP35 interacts
with both PIAS1 and IRF7 to form a larger complex. To test this
possibility, co-IP experiments were performed with cells expressing
all three proteins. In Figure 5D, Flag-IRF7 precipitated PIAS1 in
the absence of VP35, while it also precipitated VP35 in the
absence of PIAS1 (lane 6, 7), indicating that IRF7 can interact
Figure 3. VP35 does not inhibit NF-kB activation. A: DCs transduced with VP35-EGFP (VP35) or free GFP (ctrl) were infected with NDV for
indicated times and expression of Tnfa and Ikba transcripts was monitored as in Figure 2B. B: DCs transduced with VP35-HA or empty vector (ctrl)
were infected with NDV for 5 h and immunostained for HA or p65/RelA (NF-kB). About 200 DCs in three different fields were inspected to quantify
DCs showing p65 nuclear translocation.
doi:10.1371/journal.ppat.1000493.g003
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Furthermore, Flag-IRF7 co-precipitated both VP35 and PIAS1
when they were co-expressed (lane10). These data support the idea
that VP35 could interact with PIAS1 and IRF7 simultaneously by
forming a larger complex. Although there seemed a slight
reduction in the amount of precipitated PIAS1 in the presence
of VP35 (lane 7 vs. 10), multiple other experiments showed similar
amounts of PIAS1 precipitated with and without VP35,
supporting again that the three proteins interact with each other
without competition. Co-IP analysis of PIAS1 deletions, also
shown in Figure 5D, indicated that the N-terminal region of
PIAS1 is important for the interaction with IRF7 (lane 8, 9, 11,
12). In addition, we tested a series of IRF7 deletions and found
that IRF7 binds to VP35 through the two regions in the C-
terminal domain predicted to juxtapose in a 3D structure analysis
[47] (Figure S2B, S2C).
PIAS1 conjugates SUMO onto IRF7 and inhibits IFNb
promoter activity
The three-way interactions seen above, combined with
extensive reports linking SUMO modifications to transcriptional
repression, pointed to the possibility that VP35 represses IRF7-
mediated transcription through SUMO conjugation [37,38,48].
To test this possibility, we asked whether PIAS1 could SUMOylate
IRF7. Cells expressing V5-tagged SUMO3 and PIAS1-HA along
with Flag-IRF7 were immunoprecipitated with anti-Flag antibody
and tested for SUMOylation by immunoblot analysis. When
coexpressed with PIAS1, IRF7 immune precipitates displayed
extensive SUMO conjugation (see the slow migrating bands above
64 KDa, Figure 6A, upper panel). In the absence of PIAS1,
however, IRF7 precipitates showed only meager SUMO conju-
gation, indicating that PIAS1 indeed mediated IRF7 SUMOyla-
tion. To assess whether PIAS1 could SUMOylate an activated
form of IRF7, we tested a constitutively active IRF7, called 6D, in
which six serine residues in the C-terminal domain were replaced
with phosphomemic aspartic acids [49]. The IRF7 6D was also
SUMOylated by PIAS1 in a manner similar to wild type.
Immunoblot analysis of whole cell extracts showed that many
proteins were broadly SUMOylated, irrespective of PIAS1 and
IRF7 transfection, further supporting the specificity of PIAS1-
dependent IRF7 SUMOylation (Figure 6A, middle panel).
Multiple SUMO-conjugated bands found in the IRF7 precipitates
may be attributed to conjugation of polymeric SUMO chains,
although covalent binding of other peptides is another possibility
[50,51]. We found that under similar conditions, PIAS1 also
conjugated SUMO1 onto IRF7, although less robustly than
SUMO3, in line with our previous report and those indicating that
different SUMO molecules can be conjugated to a single protein
(Figure S3) [38,40,52]. To our knowledge, an E3 ligase for IRF7
has not been identified before, and this is the first report to show
that PIAS1 functions as an enzyme catalyzing IRF7 SUMOyla-
tion.
Given that SUMOylation is linked to transcriptional repression,
we then examined whether PIAS1 represses activity of IRF7 in
IFNb promoter activity. In Figure 6B, constitutive and NDV-
stimulated IFNb reporter activity was strongly enhanced by
transfection of IRF7, as expected [23,40]. However, cotransfection
of PIAS1 led to ,50% reduction in the reporter activity. As seen
in Figure 6C, IRF7 6D led to even greater enhancement than wild
type IRF7 in IFNb promoter activity, which was again repressed
by ,50% upon co-transfection of PIAS1. These data indicate that
PIAS1 represses IRF7’s transcriptional activity, consistent with the
previous reports that PIAS1 negatively regulates the activity of
several transcription factors [44,45,53,54].
Figure 4. VP35 blocks recruitment of IRF7 to the Ifna and Ifnb
genes in DCs. A: DCs transduced with VP35-HA or with control vector
were infected with NDV for 7 h and chromatin was precipitated with
anti-IRF7 antibody (solid bar) or normal rabbit IgG (open bar).
Precipitated DNA was amplified for the Ifna4 and Ifnb promoters by
q-PCR. ChIP signals are expressed as the percentage of input DNA (1%).
B: 293T cells (1610
5) were transfected with pcDNA3.1 vector for IRF7
(0.05 mg), VP35-HA (VP35) or empty vector (ctrl) (0.2 mg), along with
IFNb luciferase reporter (0.4 mg) and pRL-TK control reporter (0.01 mg)
for 24 h, and infected with NDV for 24 h. Reporter activity was
monitored by dual luciferase reporter assay. C: A549 cells (1610
5)
transfected with the vector for Flag-IRF7 (0.02 mg), increasing amounts
of VP35-HA (0.2–1 mg) and IFNb reporter (0.4 mg) plus pRL-TK (0.01 mg)
as above were infected with NDV for 24 h and reporter activity was
measured as in B. Expression of VP35-HA was verified by immunoblot
analysis in the bottom.
doi:10.1371/journal.ppat.1000493.g004
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We next tested the effect of VP35 on PIAS1-mediated IRF7
SUMOylation. Cells expressing V5-SUMO3, Flag-IRF7, VP35-
HA, and PIAS1-HA were immunoprecipitated with anti-Flag
antibody and tested for SUMO conjugation by anti-V5 antibody
(Figure 7A upper panel). IRF7 immune precipitates showed
increased SUMO conjugation in the presence of PIAS1. In the
presence of VP35, in contrast, IRF7 precipitates showed little
increase in SUMOylation under these conditions, indicating that
PIAS1, but not VP35 acted as a SUMO ligase for IRF7.
Importantly, in the presence of both PIAS1 and VP35, the levels of
SUMO conjugated IRF7 were significantly greater than those
expressing PIAS1 alone. Analysis of whole cell extracts showed
that exogenously expressed proteins were properly expressed in
these cells (Figure 7A, lower panel). In agreement with the idea
that VP35 promotes IRF7 SUMOylation, VP35, when expressed
at higher levels, increased IRF7 SUMOylation in a dose
dependent manner even in the absence of PIAS1 (Figure S4A).
To further assess the ability of VP35 to increase PIAS1-
mediated IRF7 SUMOylation, we tested a PIAS1 mutant that has
a substitution within the catalytic domain (PIAS1mu-HA) [55]. As
seen in Figure 7B, IRF7 was only minimally SUMOylated in the
presence of this mutant, unlike extensive SUMOylation observed
by the wild type PIAS1. Addition of VP35 increased the extent of
SUMOylation by the wild type PIAS1, as expected. In contrast,
there was no discernible increase in IRF7 SUMOylation by the
PIAS1 mutant. These data indicate that VP35 indeed promotes
PIAS1-mediated SUMOylation of IRF7. Since Ubc9 was found to
interact with VP35 in our yeast two-hybrid screen, we next tested
if VP35 also promotes IRF7 SUMOylation. Results in Figure 7C
show that while transfection of Ubc9 or VP35 alone increased
IRF7 SUMOylation, addition of both Ubc9 and VP35 augmented
the level of IRF7 SUMOylation.
To further substantiate the involvement of VP35 in IRF7
SUMOylation, we asked if it increases SUMO conjugation at the
previously identified single SUMO site, the lysine (K) reside at 406
[40]. As presented in Figure 7D, in the absence of VP35, wild type
IRF7 was efficiently SUMOylated by PIAS1, but not the K406R
mutant. However, in the presence of VP35, the K406R mutant
still showed SUMO conjugation, although less extensively than
wild type IRF7. Another potential SUMO conjugation site at K43
in IRF7, when mutated did not eliminate IRF7 SUMOylation in
the presence of VP35 (Figure S4B). These data indicate that VP35
promotes conjugation of SUMO molecules at multiple sites in
Figure 5. Interaction of VP35 with PIAS1 and IRF7. A: A summary of yeast two-hybrid screen. Two libraries from NDV-stimulated DCs were
screened with full length VP35 as a bait. The numbers of sequenced clones are shown. B: 293T cells (1610
6) were transfected with pcDNA3.1 vector
for full length Flag-PIAS1, or empty vector (2 mg) along with full length VP35-HA (VP35-FL) or truncated versions (2 mg each), for 30 h (see a
truncation map on top). Extracts were precipitated by anti-Flag antibody and immunoblotted with anti-HA antibody (top gel). Whole cell extracts
(WCE) were blotted with antibody to HA or Flag in the lower gels. C: Cells were transfected with indicated vector for Flag-IRF7 (2 mg) or full length or
truncated VP35-HA (2 mg), and extracts were precipitated and blotted as in A. D: Interaction of VP35 with truncated PIAS1 and IRF7. Cells were
transfected with HA-tagged full length PIAS1 (FL) (2 mg) or indicated truncations (see a PIAS1 truncation map on top) along with full length VP35-HA
and Flag-IRF7 (2 mg each) and extracts were precipitated with anti-Flag antibody, blotted with anti-HA antibody. PIAS1-N migrated just below the Ig
heavy chain (marked with *).
doi:10.1371/journal.ppat.1000493.g005
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(tagged to SUMO3) were indeed products of SUMOylation, we
tested wild type SUMO3 and the conjugation defective SUMO3
(SUMO3 G/A) in the SUMOylation assay. Data in Figure 7E
showed that wild type SUMO, but not the mutant produced
SUMO-conjugated bands for both wild type and mutant IRF7. In
line with the view that VP35 triggers IRF7 SUMOylation at
multiple K resides, a recent analysis has expanded potential
SUMOylation sites beyond the those predicted by previous models
based on the YKXE motif [56]. According to the new model, ten
additional K residues in IRF7 can potentially be SUMOylated
(Table S1). Nevertheless, given that the K406R mutant was less
efficiently SUMOylated than wild type IRF7 in the presence of
VP35, it is likely that VP35 utilizes this site as well to increase
IRF7 SUMOylation.
VP35 enhances IRF3 SUMOylation
Although not indispensable, IRF3 plays a significant role in IFN
transcription in various cell types except for pDCs [22,23,35]. In
view of the fact that VP35 inhibits IRF3’s ability to stimulate IFN
transcription and that IRF3 is SUMOylated after viral infection, it
was of interest to test if VP35 increases SUMOylation of IRF3 as
well [13,17,21,40]. As shown in Figure S5A, B,C, wild type IRF3
and IRF3 5D, a constitutively active form of IRF3 showed
increased SUMOylation in the presence of VP35: IRF3 5D was
SUMOylated to a greater extend than wild type IRF3. We also
found that VP35 inhibited IFNb promoter activity by both IRF3
and IRF3 5D under these conditions (Figure S5 D, E). These
results are consistent with the idea that VP35 inhibits IFN
transcription by promoting SUMOylation of both IRF3 and IRF7
before and after their activation.
VP35 increases inhibition of IFNb promoter activity by
IRF7
Because the combination of VP35 and PIAS1 increased IRF7
SUMOylation over that by each protein alone, it was of
importance to test if VP35 and PIAS1 together would exacerbate
the repression of IFNb transcription. In Figure 8A, NDV-induced
Figure 6. SUMOylation of IRF7 by PIAS1. A: 293T cells (1610
6) were transfected with V5-tagged SUMO3 (0.5 mg), PIAS1-HA (2 mg) along with
Flag-IRF7 or Flag-IRF7 6D (1 mg) for 30 h. Extracts were precipitated with antibody to Flag and blotted with antibody to V5. B: Cells were transfected
with PIAS1-HA (0.2 mg) or wild type IRF7 alone (0.02 mg) or together, along with IFNb reporter plus pRL-TK for 24 h followed by NDV infection for
24 h. Luciferase activity was measured as in Figure 4B. C: Above experiments were performed with IRF7 6D in place of wild type IRF7.
doi:10.1371/journal.ppat.1000493.g006
Ebola VP35 Inhibits Innate Immunity by SUMOylation
PLoS Pathogens | www.plospathogens.org 8 June 2009 | Volume 5 | Issue 6 | e1000493Figure 7. VP35 increases PIAS1 mediated IRF7 SUMOylation. A: 293T cells (1610
6) were transfected with V5-tagged SUMO3 (0.5 mg), Flag-
IRF7 (1 mg) along with PIAS1-HA (1 mg) and VP35-HA (2 mg) for 30 h (top panel). Extracts were precipitated with anti-Flag antibody and blotted with
anti-V5 antibody. Whole cell extracts were blotted with indicated antibodies (lower panels). B: Cells were transfected with V5-tagged SUMO3 and
Flag-IRF7 as above, along with wild type PIAS1-HA or a PIAS1 mutant (PIAS1mu) (1 mg) and extracts were precipitated with anti-Flag antibody and
blotted with indicated antibodies. C: Cells were transfected with V5-tagged SUMO3 and Flag-IRF7 as above, along with Ubc9 (1 mg) and extracts were
precipitated with anti-Flag antibody and blotted with indicated antibodies. D: 293T cells were transfected with V5-tagged SUMO3 (0.5 mg), Flag-wild
type IRF7 or the K406R mutant (1 mg) along with PIAS1-HA (1 mg) and VP35-HA (2 mg) (top panel). Extracts were precipitated with anti-Flag antibody
and blotted with anti-V5 antibody. Whole cell extracts were blotted with indicated antibodies (lower panels). E: Cells were transfected with V5-
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inhibition) when PIAS1 and VP35 were both expressed, compared
to when each protein was expressed alone (32 to 36% inhibition).
To ascertain whether the combination of VP35 and PIAS1 results
in greater inhibition of IFN transcription, similar assays were
conducted eight times and levels of repression was quantified in
Figure 8B. Again, the combination of the two proteins produced
greater inhibition relative to the inhibition by each protein alone
(P=0.003 to 0.00005).
We next sought to evaluate the importance of SUMO
conjugation at K406 in IRF7 in inhibition of IFNb promoter
activity, as SUMOylation of this residue appeared to be increased
by VP35 (Figure 7D). As shown in Figure 8C, VP35 inhibited
IFNb reporter activity by the K406R mutant less robustly than
that by wild type IRF7 and this effect was VP35 dose dependent
(40% inhibition by K406R vs 70% inhibition by wild type IRF7).
These data further support the view that VP35 inhibits IFN
transcription by boosting IRF7 SUMOylation.
To further evaluate the role of PIAS1 in mediating VP35’s
inhibitory effect, we next tested whether PIAS1 knockdown could
relieve VP35 inhibition of IFN reporter activity. A retroviral
vector harboring PIAS1 shRNA reduced the expression of
endogenous PIAS1 to an almost undetectable level in L292 cells.
Moreover, expression of HA-tagged wild type PIAS1, but not a
mutant PIAS1 resistant to the inhibitory effect of shRNA (PIAS1r-
HA) was also knocked down by this shRNA vector (Figure 8D). As
shown in Figure 8E (left panel), cells with PIAS1 shRNA showed
higher IFNb promoter activation by IRF7 (,1.6 fold) compared to
cells with control shRNA in the presence and absence of VP35.
Likewise PIAS1 shRNA lessened VP35 inhibition of IFNb
promoter activity after NDV stimulation (Figure 8E right panel).
In addition, in PIAS1 knockdown cells VP35 inhibited IRF7
stimulated IFNb mRNA expression less well than in control
shRNA cells, as noted by a ,3 fold increase in transcript levels
(Figure 8F). These results support the view that VP35 interacts
with PIAS1 and IRF7 and promotes IRF7 SUMOylation, leading
to efficient repression of IFNb transcription, although our data do
not exclude the possibility that VP35 may act on other SUMO
ligases to inhibit IFN transcription.
Discussion
Viruses employ diverse strategies to counter the antiviral activity
of IFNs [57]. Some RNA and DNA viruses disable IRF3 or IRF7
by modulating ubiquitination processes, thereby hastening their
degradation [22,58,59]. Some DNA viruses regulate cellular
SUMOylation processes to increase their own infectivity. ICP0,
a herpes simplex virus protein, inhibits SUMO modification of
promyelocytic leukemia protein (PML), facilitating its degradation
and the disruption of nuclear bodies [60]. The ICP0 mutation that
eliminates this activity weakens lytic infection by the virus.
Similarly, the E1E proteins of the cytomegalovirus inhibits
SUMOylation of PML and SP100, leading to the disassembly of
nuclear bodies [61]. Moreover, the adenoviral protein Gamp1
facilitates ubiquitination and degradation of SUMO E1 enzymes
to inhibit global SUMOylation [62]. However, except for a few
recent reports, SUMO modification by RNA viruses has not been
extensively reported so far [40,63].
This work began with the observations that VP35 potently
inhibits type I IFN transcription in DCs, the cell type that
produces much of the IFN in the body and that is a primary site of
early EBOV infection. Subsequent studies of underlying mecha-
nisms revealed that VP35 disables the activity of IRF7, the
transcription factor essential for type I IFN induction, by making
use of the cellular SUMOylation machinery.
VP35 action in DCs
The inhibition of NDV-induced IFN transcription by VP35 in
both pDCs and cDCs noted in this work is in agreement with
previous investigations of VP35 activity in non-DCs [13,17,20].
Nevertheless, our results differ from those of previous reports in
several important aspects. First, the effect of VP35 was previously
ascribed to reduced activation of IRF3, a factor that has since been
shown to be dispensable for IFN induction in various cell types
including DCs [22,23], whereas our study primarily focused on
VP35 inhibition of IRF7, a factor known to be critically required
for IFN transcription, particularly in DCs. In addition, the
dsRNA-binding activity mapped to the C-terminal region of VP35
was previously proposed to be important for inhibition of IFN
production, although these studies predicted the presence of an
additional mechanism by which VP35 inhibits IFN production
[17,21]. We noted that VP35 inhibits CpG DNA-mediated IFN
transcription, consistent with an inhibitory mechanism indepen-
dent of dsRNA-binding activity. We also found that the N-
terminal half of VP35 was required for inhibition of IFN
transcription, in addition to the C-terminal half. The N-terminal
VP35 was subsequently found essential for the interaction with
IRF7 and PIAS1, through which VP35 inhibited IFN transcrip-
tion. Thus, it seems reasonable to suggest that the enhanced
SUMOylation of IRF7 by VP35 observed in this work represents
the missing mechanism foreseen by earlier studies [17].
Another notable aspect of our findings is that while VP35
strongly inhibited IFN transcription, it only marginally affected
NF-kB activation, as evidenced by intact IkBa induction and
normal nuclear translocation of p65/RelA in VP35 expressing
DCs. This result is interesting, since NF-kB is essential for the
expression of many pro-inflammatory cytokines and chemokines
[42,43]. The selective abrogation of IRF7 activation, sparing NF-
kB activation is reminiscent of the characteristic pathogenesis of
EBOV infection, in which impaired IFN induction accompanies
copious production of other proinflammatory cytokines [6,7].
VP35 exploits the cellular SUMOylation machinery to
inhibit IRF7 activation
Results of yeast two-hybrid screens and the subsequent Co-IP
experiments revealed a clear link between VP35 and SUMO
modification: VP35 formed a complex with the SUMO ligase
PIAS1 and IRF7, augmented PIAS1-mediated IRF7 SUMOyla-
tion, and increased the repression of IFN promoter activity
(Diagram in Figure 8G). One can envisage that VP35, although
not itself a SUMO E3 ligase, brings IRF7 to the cellular SUMO
machinery, causing increased IRF7 SUMOylation and decreased
IFN transcription. The observations that both the wild-type and
constitutively active IRF7 were SUMOylated by PIAS1, and that
VP35 inhibited activities of both forms of IRF7, indicate that
VP35 can promote SUMOylation of IRF7 before and after
tagged wild type SUMO3 or a conjugation-defective SUMO3 mutant (SUMO3 G/A, see a diagram on the right) (0.5 mg), Flag-tagged wild type IRF7,
K406R, or K43R (1 mg) and VP35-HA (2 mg) for 30 h (top panel). Extracts were precipitated with anti-Flag antibody and blotted with anti-V5 antibody.
Whole cell extracts were blotted with indicated antibodies (lower panels).
doi:10.1371/journal.ppat.1000493.g007
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PLoS Pathogens | www.plospathogens.org 10 June 2009 | Volume 5 | Issue 6 | e1000493Figure 8. VP35 Increases IRF7 SUMOylation. A: Cells were transfected with PIAS1-HA or VP35-HA or both, a vector for IRF7 (0.02 mg each), and
IFNb reporter plus pRL-TK and stimulated with NDV for 24 h, and luciferase activity was measured as in Figure 4B (top panel). B: Experiments above
were performed eight times each with triplicate determinations and levels of repression was averaged and quantified. C: Cells were transfected with
two doses of VP35 with wild type IRF7 or IRF7 K406R (0.02 mg), along with IFNb reporter plus pRL-TK for 24 h followed by NDV infection 24 h.
Luciferase activity was measured as in Figure 4B. D: L929 cells (1610
6) transduced with control or PIAS1 shRNA retroviral vector. Some cells were also
transduced with wild type PIAS1-HA or PIAS1r-HA vector that is resistant to PIAS1 shRNA. While cell extracts were blotted with anti-PIAS1 antibody. *
denotes a nonspecific band. E: L929 cells (1610
5) transduced with control or PIAS1 shRNA vector were transfected with VP35-HA, IRF7 (0.02 mg each)
and IFNb reporter plus pRL-TK and with or without stimulation by NDV for 24 h, and luciferase activity was measured as in Figure 8A. F: NIH3T3 cells
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SUMOylation, we noted that VP35 also increases SUMO
conjugation of wild type and an active form of IRF3. The idea
that VP35 makes use of the cellular SUMO system is further
supported by our recent report that both IRF3 and IRF7 are
SUMOylated following viral infection [40]. It is likely that IRF7
SUMOylation represents a feedback mechanism by which to
attenuate IFN transcription post-activation, allowing cells to limit
excessive inflammatory responses [64]. Our results are consistent
with the view that VP35 prematurely causes extensive IRF7
SUMOylation (and that of IRF3 in some cells) to halt the
transcriptional activation of Ifn genes. In that study, we showed
that IRF7 is SUMOylated mainly at K406, leading to reduced
IFN production. Our present analyses indicate that VP35 triggers
in SUMOylation of not only this site but additional K residues.
In this paper we show that PIAS1 conjugates SUMO1 and
SUMO3 to IRF7 and represses IRF7 dependent IFN transcrip-
tion. To our knowledge, a SUMO E3 ligase for IRF7 has not been
identified to date, and this is the first demonstration that PIAS1
serves as an E3 ligase for IRF7. We found that the combination of
VP35 and PIAS1 exacerbated inhibition of IFN transcription,
consistent with the idea that VP35 promotes IRF7 SUMOylation
through PIAS1. This idea is further supported by the observation
that this inhibition was relieved by PIAS1 shRNA. While our data
point to a significant role for PIAS1 in VP35 mediated repression
of IFN transcription, it is possible that VP35 mobilizes other
ligases to achieve greatest inhibition of IFN induction. PIAS1
belongs to the PIAS family, which includes three additional
members [65]. The founding member, PIAS1, inhibits STAT1
activation to block the expression of some, but not all IFN-
responsive genes [45]. Pias1 2/2 macrophages are, thus,
hypersensitive to IFN stimulation [45]. Although a previous report
showed that PIAS1 inhibits the DNA-binding activity of STAT1
independent of SUMOylation, a more recent study showed that it
also SUMOylates STAT1 [44,54]. These and additional reports
that PIAS family proteins conjugate SUMO molecules onto IRF1
and IRF2 appear to support a role for the PIAS family in
regulating the IFN system [40,51,66].
A large body of literature illustrates a strong link between
SUMOylation and transcriptional repression through multiple
mechanisms [37,38,65]. For example, SUMO modification
influences nuclear-cytoplasmic transport of a number of proteins,
while some SUMOylated transcription factors repress transcrip-
tion by interfering with their nuclear retention and/or export
[37,38]. SUMO-conjugated proteins may also be recruited to a
region of repressed chromatin, as reported for the recruitment of
SUMOylated homeodomain-interacting protein kinase 2 to
nuclear bodies [67]. Similarly, SUMO-conjugated Sp3 is seques-
tered in nuclear bodies [68]. Finally, SUMO-modified proteins
such as p300, ELK, and PPARc recruit co-repressors and histone
deacetylases to establish a repressive chromatin environment
[37,65,69]. This mechanism may explain how SUMOylated
proteins, which make up only a fraction of the total proteins, can
cause transcriptional repression. At present it is uncertain exactly
how SUMOylated IRF7 blocks IFN transcription, although it is
clear that it disables recruitment to Ifn genes.
In summary, this work describes a viral strategy that exploits the
host SUMOylation system to inactivate antiviral innate immunity.
It will be of importance to elucidate the mechanism by which
SUMO-modified IRF7 represses IFN gene transcription in DCs.
Materials and Methods
Plasmids and retroviral vectors
cDNAs encoding VP35 and VP24 of the mouse-adapted EBOV
were generated by site directed mutagenesis from the pcDNA3.1
plasmids harboring VP35 and VP24 of the Zaire subtype EBOV
using the QuikChange kit (Stratagene). cDNAs for VP35 and VP24
were cloned into appropriate plasmid vectors to fuse to the EGFP-
or HA at the C-terminus and the fused cDNAs were then inserted
into pMSCV-puro vector (Clontech). Viral supernatants were
prepared from 293ET cells transfected with the above vectors, plus
plasmids for VSV-G envelope and gag/pol. Mouse full-length
PIAS1 was cloned from IFNb-stimulated NIH3T3 cells and
inserted into pcDNA3.1 with a Flag or HA tag. The HA-tagged
PIAS1 mutant in which the cysteine at 351 was replaced by serine
was constructed in pcDNA3.1 by site directed mutagenesis.
SUMO3 cDNA was cloned in pcDNA3.1 with a V5-tag at the N-
terminus. The V5-tagged SUMO3-G/A in pcDNA3.1 was
constructed by replacing two glycines to alanines at aa 91 and 92
by site direct mutagenesis. All resultant constructs were sequenced
to verify correct cloning. Expression vectors for mouse IRF7, IRF7
K406R, IRF7 K43R, IRF3 and IRF3 5D in pcDNA3.1 and the
IFNb promoter construct were described [40]. Deletion constructs
for VP35, PIAS1 or IRF7 were prepared by standard cloning
procedures. The PIAS1 shRNA retroviral vector was constructed in
pSUPERretro vector (Oligoengine) by inserting gaaaccagttgtcca-
caagaa which targets nucleotide position 624–644 of mouse PIAS1.
L929 or NIH3T3 cells were transduced with the shRNA retroviral
vectororcontrolshRNAvectoressentiallyasdescribed [70].Briefly,
cells were transduced with viral supernatants by spinoculation twice
over two consecutive days and were selected by puromycin (2 mg/
ml) for 3 days prior to use. Antibodies for Flag-conjugated to beads,
(M2), HA, V5 and PIAS1 were obtained from Sigma, Roche,
Invitrogen and Epitomics, respectively.
BMDCs and viral transduction
All animal work performed under protocols approved the
animal care and use committees of NICHD. BMDCs were
generated in the presence of Flt3L from C57BL/6 mice as
described [36,71]. Two days following the initiation of culture,
cells were transduced with pMSCV vectors for VP35-EGFP,
VP35-HA, free EGFP, or without insert by two consecutive
spinoculations. Cells were selected by 1 mg/ml puromycin for the
remaining period. On day 7 or day 8, cells were infected with
NDV (Heartz strain) at a MOI of 2 or stimulated with CpG
(ODN1826, Invitrogen) or IFNb (PBL) at indicated concentrations
for indicated periods.
Flow cytometry and immunostaining
To monitor DC surface markers, cells were incubated with
Phycoerythrin-conjugated B220/CD45R and biotin conjugated
(1610
5) transduced with control or PIAS1 shRNA vector were further transduced with both of IRF7 and VP35 for 3 days. Cells were then infected with
NDV for 24 h and IFNb transcripts were measured in Figure 2C. G: A model for VP35 action. VP35 interacts with the host SUMOylation machinery,
including Ubc9 and PIAS1, the SUMO E2 enzyme and E3 ligase, respectively. VP35 also interacts with IRF7 (and IRF3) bringing IRF7 (and IRF3) to the
SUMOylation machinery, and promotes extensive SUMOylation of IRF7 (and IRF3). The premature SUMOylation of the IRFs abrogates their ability to
activate IFN transcription causing diminished IFN production. It should be noted (i) VP35 has additional mechanisms of inhibiting IFN transcription
and (ii) VP35 may involve other SUMO E3 ligases to increase IRF7 SUMOylation.
doi:10.1371/journal.ppat.1000493.g008
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erythrin-Cy5 (both from BD Pharmingen). Stained cells were
analyzed on FACSCaliber (Becton Dickinson) and data were
processed by the FlowJo software. For immunostaining, DCs were
placed on cytospin slides and fixed with 4% paraformaldehyde,
permeabilized with 0.5% Triton X-100 and stained with indicated
antibodies as described [71]. To detect HA-tagged VP35, cells
were stained with anti-HA antibody (Roche) followed by Alexa-
Fluor 568 conjugated goat anti-rat IgG (Molecular Probes),
counterstained with Hoechst 33342. Stained cells were viewed
on a Leica Model TCS-SP2 confocal microscope.
Quantitative RT-PCR
cDNA was synthesized from 0.5 mg of total RNA from indicated
DCs using SuperScript II reverse transcriptase (Invitrogen). PCR
amplification was performed with 4 ng of cDNA in 10 mlo f
SYBER Green PCR Master Mix (Applied Biosystems) with 3 mM
of primers in the ABI prism 7500 fast Real-Time PCR System
(Applied Biosystems). DC supernatants were tested for IFNa
production using the mouse IFNa ELISA Kit (PBL).
Yeast two-hybrid screen
Two cDNA libraries were constructed from DCs stimulated
with NDV for 6 h in pDEST22 vector using the CloneMiner
cDNA Library Construction Kit (Invitrogen) according to the
manufacture’s designated procedures. Both libraries had the
average insert size of ,1.5 kbp. 4.41610
6 yeast clones were
screened with ProQuest two-hybrid system (Invitrogen) with the
full length VP35 as a bait, and resultant 317 positive clones were
sequenced.
Coimmunoprecipitation, immunoblot and SUMO
conjugation assay
293T cells (1610
6) were transfected with indicated expression
vectors for 30 h, extracts were prepared in 500 ml lysis buffer (1%
NP40, 50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 2.7 mM KCl).
Four hundred ml of lysates were incubated with anti-Flag antibody
beads (Sigma) for overnight, and precipitates were eluted with
50 ml of sample buffer by boiling, and 20 ml of immunoprecipitates
and 4% of whole cell extracts, used for the loading control, were
resolved on 4–12% NuPAGE (Invitrogen) and immunoblotted
with indicated antibodies as described [40]. For SUMOylation
assay, 293T cells transfected with pcDNA3.1 for IRF7 or IRF3,
PIAS1, VP35 along with V5-SUMO3 for 30 h. Extract prepara-
tions, immunoprecipitation and immunoblotting were performed
according to the described method [72].
Luciferase reporter analysis
293T or A549 cells were transfected with the indicated amounts
of pGL4 vector with the IFNb promoter and pRL-TK reporters
along with other expression vectors using the FuGENE 6
Transfection Reagent (Roche) for 24 h, and were infected with
NDV for 24 h [40]. Lysates were analyzed for luciferase activity
using the dual-luciferase assays kit (Promega). IFNb reporter
activity was normalized by Renilla luciferase activity.
Supporting Information
Figure S1 VP35 from Zaire EBOV (hVP35) and mouse-adapted
EBOV (mVP35) both inhibit type I IFN expression in murine
DCs. (A) VP35 from human and mouse EBOVs were tagged to
EGFP and cloned in pcDNA3.1 and transfected into 293T cells
(3610
5 cells). Whole cell extracts harvested 24 h after transfection
were tested by immunoblot using anti-GFP antibody. (B) BMDCs
were transduced with pMSCV with hVP35-EGFP or free EGFP
(Ctrl) on day 2; cells were stimulated with NDV on day 8 for 5 h.
IFNa proteins and transcripts were measured by ELISA and qRT-
PCR, respectively. Values represent the average of three assays+/
2S.D. (C) Above DCs were stimulated with NDV or CpG DNA
and Ifn{lower case betaa} or Ifna transcripts were measured as
above. (D) DCs transduced with hVP35-HA, mVP35-HA or free
EGFP (Ctrl) were infected with NDV for 7 h and chromatin was
precipitated with anti-IRF7 antibody (solid bar) or normal rabbit
IgG (open bar). Precipitated DNA was amplified for the Ifna4 and
Ifnb promoters by q-PCR. ChIP signals are expressed as the
percentage of input DNA (1%).
Found at: doi:10.1371/journal.ppat.1000493.s001 (2.31 MB TIF)
FigureS2 InteractionofVP35withIRF7.(A)VP35interactswith
IRF7 before and after NDV infection. 293T cells (1610
6) were
transfected with pcDNA3.1 vector for Flag-IRF7 (2 mg) and VP35-
HA (2 mg) for 24 h and infected with or without NDV for 24 h.
Extracts were precipitated with anti-Flag antibody and blotted with
anti-HA antibody. Whole cell extracts (WCE) were blotted with
indicated antibodies to verify expression of transfected proteins. (B)
VP35 bindstotwoseparate domains ofIRF7.Schematicdiagram of
IRF7 deletions.Resultsofdomainanalysisaresummarized onright.
(C) 293T cells were cotransfected with pcDNA3.1 vector for VP35-
HA (2 mg) and Flag-IRF7 deletion constructs (2 mg) for 24 h. The
extracts were immunoblotted with indicated antibodies. The two
regions through which VP35 interacts with IRF7 are predicted to
juxtapose in crystallography [47].
Found at: doi:10.1371/journal.ppat.1000493.s002 (1.90 MB TIF)
Figure S3 PIAS1 mediates SUMO1 conjugation to IRF7. 293T
cells were transfected with T7-tagged SUMO1 (0.5 mg), PIAS1-
HA (2 mg) along with Flag-IRF7 or Flag- IRF7 6D (1 mg) for 30 h.
Extracts were precipitated with anti-Flag antibody and blotted
with antibody to T7.
Found at: doi:10.1371/journal.ppat.1000493.s003 (0.64 MB TIF)
Figure S4 VP35 triggers IRF7 SUMOylation. (A) 293T cells
(1610
6) were transfected with V5-tagged SUMO3 (0.5 mg), Flag-
IRF7 (1 mg) and VP35-HA (0.5 and 1 mg) for 30 h. Extracts were
precipitated with antibody to Flag and blotted with antibody to
V5. (B) Cells were transfected with V5-tagged SUMO3 (0.5 mg),
VP35-HA (2 mg) along with Flag-IRF7, Flag-IRF7 K406R or
Flag-IRF7 K43R (1 mg) and tested as above.
Found at: doi:10.1371/journal.ppat.1000493.s004 (1.66 MB TIF)
Figure S5 VP35 enhances IRF3 SUMOylation.(A) Interaction of
VP35 with IRF3. Cells (1610
6) were transfected with HA-tagged
VP35 (2 mg) Flag- IRF3 (2 mg each) and extracts were precipitated
with anti-Flag antibody, blotted with anti-HA antibody. (B) 293T
cells were transfected with V5-tagged SUMO3 (0.5 mg), VP35-HA
(2 mg) along with Flag-IRF3 or Flag-IRF3 5D (1 mg) for 30 h.
Extracts were precipitated with antibody to Flag and blotted with
antibody to V5. (C) 293T cells (1610
6) were transfected with
increasing doses of VP35-HA (0.5 mg, 1 mg and 2 mg) along with
Flag-IRF3 5D (1 mg) for 30 h. Extracts were precipitated with
antibody to Flag and blotted with antibody to V5. (D) Cells were
transfected with VP35-HA (0.5 mg) or IRF3 5D alone (0.1 mg) or
together, along with IFNb reporter plus pRL-TK for 24 h and then
NDV infection. Post infection 24 h, the cell lysates were harvested
for dual Luciferase activity. (E) The Luciferase assay was performed
as in (C). The VP35 inhibition of IRF3 and IRF3 5D activity was
calculated relative to the control activity without VP35 expression.
Found at: doi:10.1371/journal.ppat.1000493.s005 (1.67 MB TIF)
Table S1 The potential SUMO conjugation sites in the mouse
IRF7 predicted by the SUMOsp software by Xue Y., et al (http://
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be SUMOylated [40]. However, our data in Figure 7 indicate that
VP35 promotes SUMO conjugation at this and additional sites,
supported by this prediction.
Found at: doi:10.1371/journal.ppat.1000493.s006 (0.03 MB
DOC)
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